Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 12/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | KCNK5 | O95279 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | KCNK17 | Q96T54 | 1/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125401 | 0.87 | P2RX7 (0.44) | P2RX7ADORA2AADORA1ALDH1A1MAPK1 | |
| SCHEMBL5129246 | 0.82 | ADORA2A (0.40) | P2RX7ADORA2AADORA1ALDH1A1MAPK1 | |
| SCHEMBL5249953 | 0.82 | P2RX7 (0.48) | P2RX7HSD17B13 | |
| SCHEMBL5129244 | 0.80 | P2RX7 (0.39) | P2RX7ADORA2AADORA1ALDH1A1MAPK1 | |
| SCHEMBL5129254 | 0.79 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1 | |
| SCHEMBL5128797 | 0.78 | P2RX7 (0.44) | P2RX7ADORA2AADORA1ALDH1A1 | |
| SCHEMBL5130363 | 0.75 | P2RX7 (0.48) | P2RX7ALDH1A1 | |
| SCHEMBL5130148 | 0.74 | ALDH1A1 (0.54) | ALDH1A1MAPK1 | |
| SCHEMBL5121872 | 0.74 | ROCK2 (0.50) | ADORA2AALDH1A1MAPK1 | |
| SCHEMBL5117478 | 0.74 | MEN1 (0.48) | ADORA2AADORA1ALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459452-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-12-02 | — | — | US | disclosed |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DI FRANCESCO MARIA E | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DUT, DPYD, TYMP | P2RX7 1779/4885ADORA2A 1965/4885ADORA1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.